Financial Performance Highlights
- H1 FY27 Consolidated Revenue: ₹411 crore
- H1 FY27 EBITDA Margin: 18.82% (slightly higher than Q1 FY27's 17.6%)
- H1 FY27 PAT Margin: 11.88% (significantly higher than Q1 FY27's 10.78%)
- FY27 Revenue Guidance: ₹1,550 crore (conservative estimate, management expects to surpass by 10-15%)
- FY27 PAT Guidance: ₹170-175 crore
- Revenue Concentration: Approximately 50% of budgeted FY27 revenue achieved in first two quarters, with major revenue expected in remaining two quarters
Business Division Updates
Medical Technology (MedTech) Division:
- Contributes 10-15% of current healthcare business (which represents 60% of total business)
- Renalyx RXT 21 AI Dialysis Machine:
- Production commenced at Bangalore facility
- Clinical trials ongoing at specialized healthcare centers
- 500+ confirmed export orders (UK, USA, Africa, Nepal, Bangladesh)
- 350+ confirmed domestic orders
- Execution timeframe: 6-9 months
- CE certified and US approved
- Cost of ownership 30-40% lower than imported machines over 5-7 years
IVD Business:
- 700+ distributors, 200+ enterprise clients
- Presence in 15 high-density states
- 26 additional IVD medical devices manufacturing licenses received in Q2
- Expanding to SAARC countries and US exports
Product Launch Roadmap:
- December 2026: Commercial shipments of dialysis machines begin with export orders
- January 2027: Sickle cell screening launch (subject to manufacturing license receipt); UK product sales begin
- February 2027: UK operations start; AI-based medical device for physicians launch; CAR-T clinical trials begin
- March 2027: US sales start (subject to US FDA approval); Caribbean export sales begin; Gut microbiome testing commercial rollout
- March 2028: Third IVD manufacturing plant operational
- June 2028: Advanced CAR-T treatment centers operational (subject to CDSCO approval)
Renewable Energy Division:
- ₹3,000+ crore order pipeline backed by Maha PSU and government relationships
- Orders spread over 3-5 year execution period
- Approximately ₹300-400 crore executed in H1 FY27
- Demerger planned by March 2027 (subject to NCLT approval, may spill to Q1 FY28)
Subsidiary Updates
- US Subsidiary: Lord's Mark Industries Incorporation established; plans to set up dedicated laboratory and export full range of IVD/surgical products from India
- UK Subsidiary: Secured all necessary MHRA approvals including for AI dialysis machine; sales to begin January 2027
- Caribbean Operations: Plan to launch pathology laboratory chain with local partners from March 2027
Technology and Innovation
- 30+ registered brands, 139 registered trademarks
- Exclusive licenses from IIT Bombay, BARC, C-MET, BITS Pilani
- Regulatory approvals: CDSCO, CE certification, MHRA UK, US FDA applied for
- Flagship innovations:
- Renalyx AI dialysis ecosystem with remote monitoring capabilities
- AI-based radiation-free breast cancer screening device
- Onco Diagnoscope for oral cancer diagnosis without biopsy
- Sickle cell testing technology (15-minute results vs. 72 hours conventional)
- Gut microbiome testing (CDSCO approval received)
- CAR-T therapy addressing 18 cancer types (clinical trials begin February 2027)
Financial Disclosure Incident
- Management acknowledged publishing two different versions of financial results signed by authorized signatories
- Described as an "inadvertent error" by accounts team
- Board has set up committee to monitor future publications and prevent recurrence
- Letter submitted to exchange acknowledging error
- Management expressed regret and embarrassment over the incident
Funding and Capital Structure
- Promoter sold approximately 5% equity to maintain 75% minimum shareholding
- ₹170 crore re-infused back into company by promoter
- Company described as "adequately funded" for current requirements
- Capex requirement for next financial year (FY28) for Asia's largest IVD/MedTech factory in Vapi or Lucknow
Market Strategy
- Competitive Differentiation: Technology innovation, price advantage, indigenous manufacturing (85% parts in-house)
- Go-to-market: Retail hospitals/clinics, government partnerships, export markets (UK, USA, GCC, SAARC)
- Brand Ambassador: Rahul Dravid for IVD and pathology business
Manufacturing Capabilities
- ISO certified devices
- GMP compliant plants
- Second plant operational, third plant commissioning soon
Q&A Session Highlights
- Management addressed concerns about financial reporting reliability
- Detailed technology exclusivity agreements with IIT Bombay and BARC
- Explained competitive advantages in dialysis machines and diagnostic equipment
- Discussed genome testing focus areas: preventive genomics, gut microbiome, pharmacogenomics
- Addressed stock price performance constraints due to T2T segment status